Elaine Ku1,2, Joachim H Ix3,4, Kenneth Jamerson5, Navdeep Tangri6, Feng Lin7, Jennifer Gassman8, Miroslaw Smogorzewski9, Mark J Sarnak10. 1. Division of Nephrology, Department of Medicine, elaine.ku@ucsf.edu. 2. Division of Pediatric Nephrology, Department of Pediatrics, and. 3. Division of Nephrology, Department of Medicine, University of California, San Diego, La Jolla, California. 4. Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California. 5. Division of Cardiovascular Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan. 6. Division of Nephrology, University of Manitoba, Winnipeg, Manitoba, Canada. 7. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. 8. Division of Quantitative Sciences, Cleveland Clinic Foundation, Cleveland, Ohio. 9. Division of Nephrology and Hypertension, Department of Medicine, University of Southern California, Los Angeles, California; and. 10. Division of Nephrology, Department of Medicine, Tufts University, Boston, Massachusetts.
Abstract
BACKGROUND: During intensive BP lowering, acute declines in renal function are common, thought to be hemodynamic, and potentially reversible. We previously showed that acute declines in renal function ≥20% during intensive BP lowering were associated with higher risk of ESRD. Here, we determined whether acute declines in renal function during intensive BP lowering were associated with mortality risk among 1660 participants of the African American Study of Kidney Disease and Hypertension and the Modification of Diet in Renal Disease Trial. METHODS: We used Cox models to examine the association between percentage decline in eGFR (<5%, 5% to <20%, or ≥20%) between randomization and months 3-4 of the trials (period of therapy intensification) and death. RESULTS: In adjusted analyses, compared with a <5% eGFR decline in the usual BP arm (reference), a 5% to <20% eGFR decline in the intensive BP arm was associated with a survival benefit (hazard ratio [HR], 0.77; 95% confidence interval [95% CI], 0.62 to 0.96), but a 5% to <20% eGFR decline in the usual BP arm was not (HR, 1.01; 95% CI, 0.81 to 1.26; P<0.05 for the interaction between intensive and usual BP arms for mortality risk). A ≥20% eGFR decline was not associated with risk of death in the intensive BP arm (HR, 1.18; 95% CI, 0.86 to 1.62), but it was associated with a higher risk of death in the usual BP arm (HR, 1.40; 95% CI, 1.04 to 1.89) compared with the reference group. CONCLUSIONS: Intensive BP lowering was associated with a mortality benefit only if declines in eGFR were <20%.
RCT Entities:
BACKGROUND: During intensive BP lowering, acute declines in renal function are common, thought to be hemodynamic, and potentially reversible. We previously showed that acute declines in renal function ≥20% during intensive BP lowering were associated with higher risk of ESRD. Here, we determined whether acute declines in renal function during intensive BP lowering were associated with mortality risk among 1660 participants of the African American Study of Kidney Disease and Hypertension and the Modification of Diet in Renal Disease Trial. METHODS: We used Cox models to examine the association between percentage decline in eGFR (<5%, 5% to <20%, or ≥20%) between randomization and months 3-4 of the trials (period of therapy intensification) and death. RESULTS: In adjusted analyses, compared with a <5% eGFR decline in the usual BP arm (reference), a 5% to <20% eGFR decline in the intensive BP arm was associated with a survival benefit (hazard ratio [HR], 0.77; 95% confidence interval [95% CI], 0.62 to 0.96), but a 5% to <20% eGFR decline in the usual BP arm was not (HR, 1.01; 95% CI, 0.81 to 1.26; P<0.05 for the interaction between intensive and usual BP arms for mortality risk). A ≥20% eGFR decline was not associated with risk of death in the intensive BP arm (HR, 1.18; 95% CI, 0.86 to 1.62), but it was associated with a higher risk of death in the usual BP arm (HR, 1.40; 95% CI, 1.04 to 1.89) compared with the reference group. CONCLUSIONS: Intensive BP lowering was associated with a mortality benefit only if declines in eGFR were <20%.
Authors: Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: Paul M Palevsky; Jane H Zhang; Stephen L Seliger; Nicholas Emanuele; Linda F Fried Journal: Clin J Am Soc Nephrol Date: 2016-09-27 Impact factor: 8.237
Authors: Carmen A Peralta; Leslie A McClure; Rebecca Scherzer; Michelle C Odden; Carole L White; Michael Shlipak; Oscar Benavente; Pablo Pergola Journal: Circulation Date: 2016-01-13 Impact factor: 29.690
Authors: Michael V Rocco; Kaycee M Sink; Laura C Lovato; Dawn F Wolfgram; Thomas B Wiegmann; Barry M Wall; Kausik Umanath; Frederic Rahbari-Oskoui; Anna C Porter; Roberto Pisoni; Cora E Lewis; Julia B Lewis; James P Lash; Lois A Katz; Amret T Hawfield; William E Haley; Barry I Freedman; Jamie P Dwyer; Paul E Drawz; Mirela Dobre; Alfred K Cheung; Ruth C Campbell; Udayan Bhatt; Srinivasan Beddhu; Paul L Kimmel; David M Reboussin; Glenn M Chertow Journal: Am J Kidney Dis Date: 2017-11-20 Impact factor: 8.860
Authors: Alfred K Cheung; Mahboob Rahman; David M Reboussin; Timothy E Craven; Tom Greene; Paul L Kimmel; William C Cushman; Amret T Hawfield; Karen C Johnson; Cora E Lewis; Suzanne Oparil; Michael V Rocco; Kaycee M Sink; Paul K Whelton; Jackson T Wright; Jan Basile; Srinivasan Beddhu; Udayan Bhatt; Tara I Chang; Glenn M Chertow; Michel Chonchol; Barry I Freedman; William Haley; Joachim H Ix; Lois A Katz; Anthony A Killeen; Vasilios Papademetriou; Ana C Ricardo; Karen Servilla; Barry Wall; Dawn Wolfgram; Jerry Yee Journal: J Am Soc Nephrol Date: 2017-06-22 Impact factor: 10.121
Authors: Elaine Ku; David V Glidden; Kirsten L Johansen; Mark Sarnak; Hocine Tighiouart; Barbara Grimes; Chi-Yuan Hsu Journal: Kidney Int Date: 2014-12-10 Impact factor: 10.612
Authors: Didier Collard; Tom F Brouwer; Rik H G Olde Engberink; Aeilko H Zwinderman; Liffert Vogt; Bert-Jan H van den Born Journal: Hypertension Date: 2020-03-30 Impact factor: 10.190